Torrent Pharmaceuticals Limited — Important, 24-01-2025: Updates

**Torrent Pharmaceuticals Limited Update**

Torrent Pharmaceuticals has reported its Q3 FY25 financial results, showcasing a resilient net profit of ₹503 crore, marking a 14% year-over-year growth. Total revenue for the quarter reached ₹2,809 crore, reflecting a 3% increase, driven by strong domestic performance despite challenges in the Brazilian market due to a 17% depreciation of the BRL. Operating EBITDA showed a positive trajectory, rising to ₹914 crore with a margin of 32.5%.

The Indian market performed notably well, with revenue increasing by 12% to ₹1,581 crore, outpacing industry growth. Torrent's initiatives in chronic therapies contributed significantly, further highlighted by the performance of its top brands. Conversely, revenues in Brazil dipped by 7%, though constant currency performance remained robust.

Overall, Torrent's strategic focus on R&D and expansion plans positions it well for future growth. Investors should watch closely as the company navigates region-specific challenges while capitalizing on its market strengths.